Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Single Arm, Prospective, Open-label, Multi-center Study to Evaluate Efficacy and Safety in Chinese Patients with Late Onset Pompe Disease with Alglucosidase Alfa Treatment

    Summary
    EudraCT number
    2024-000461-24
    Trial protocol
    Outside EU/EEA  
    Global end of trial date
    25 Jul 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    01 Feb 2025
    First version publication date
    01 Feb 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    ALGMYL09010 / LPS15677
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04676373
    WHO universal trial number (UTN)
    U1111-1238-1267
    Sponsors
    Sponsor organisation name
    Sanofi China Investment Co.,Ltd
    Sponsor organisation address
    Floor 7, No. 112, Jianguo Road, Chaoyang District, Beijing, China,
    Public contact
    Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com
    Scientific contact
    Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    11 Nov 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    25 Jul 2024
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    - To evaluate the effect of alglucosidase alfa (Myozyme) treatment on motor function (Six-minute walk test [6MWT] and lung function (predicted Forced vital capacity [FVC]) among Chinese late-onset pompe disease (LOPD) participants above 5 years old. - To evaluate the safety of alglucosidase alfa (Myozyme) 20 milligram per kilogram (mg/kg), intravenous (IV) biweekly in Chinese LOPD participants above 3 years old.
    Protection of trial subjects
    The study was conducted by investigators experienced in the treatment of pediatric participants. The parent(s) or guardian(s) as well as the children were fully informed of all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time. In addition to the consent form for the parent(s)/guardian(s), as assent form in child-appropriate language was provided and explained to the child. Repeated invasive procedures were minimized. The number of blood samples as well as the amount of blood drawn were adjusted according to age and weight. A topical anesthesia may have been used to minimize distress and discomfort.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    10 Mar 2021
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    China: 41
    Worldwide total number of subjects
    41
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    2
    Adolescents (12-17 years)
    14
    Adults (18-64 years)
    25
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study was conducted at 10 centers in China. A total of 43 participants were screened from 10 March 2021 to 01 June 2023, of which 2 were screen failures. Screen failures were mainly due to not meeting the eligibility criteria.

    Pre-assignment
    Screening details
    A total of 41 participants with LOPD received alglucosidase alfa in the study.

    Period 1
    Period 1 title
    Overall study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    Alglucosidase alfa
    Arm description
    Participants received alglucosidase alfa at a dose of 20 mg/kg body weight every 2 weeks as an IV infusion for up to 52 weeks.
    Arm type
    Experimental

    Investigational medicinal product name
    Alglucosidase alfa
    Investigational medicinal product code
    Other name
    MYOZYME®
    Pharmaceutical forms
    Powder for injection
    Routes of administration
    Intravenous use
    Dosage and administration details
    Participants received alglucosidase alfa at a dose of 20 mg/kg body weight every 2 weeks as an IV infusion using an infusion pump, over approximately 4 hours.

    Number of subjects in period 1
    Alglucosidase alfa
    Started
    41
    Completed
    36
    Not completed
    5
         Consent withdrawn by subject
    3
         Adverse event, non-fatal
    1
         Coronavirus Disease-2019 (COVID-19)
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Alglucosidase alfa
    Reporting group description
    Participants received alglucosidase alfa at a dose of 20 mg/kg body weight every 2 weeks as an IV infusion for up to 52 weeks.

    Reporting group values
    Alglucosidase alfa Total
    Number of subjects
    41 41
    Age Categorical
    Units: Subjects
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    24.2 ( 11.17 ) -
    Gender Categorical
    Units: Participants
        Female
    21 21
        Male
    20 20
    Percentage of Predicted Forced Vital Capacity (FVC)
    FVC is a measurement of pulmonary function which is defined as the volume of air that can forcibly be blown out after full inspiration. It was assessed using the spirometry system with the participant in upright seated position. Percent of predicted FVC = (actual FVC measurement)/(predicted value of FVC) x 100.
    Units: Percentage of Predicted FVC
        arithmetic mean (standard deviation)
    49.777 ( 14.992 ) -
    Six-Minute Walk Test (6MWT)
    The 6MWT is a practical simple test that measures the distance that a participant can quickly walk on a flat, hard surface in a period of 6 minutes. It evaluates the global and integrated responses of all the systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism.
    Units: Meters
        arithmetic mean (standard deviation)
    390.282 ( 101.928 ) -

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Alglucosidase alfa
    Reporting group description
    Participants received alglucosidase alfa at a dose of 20 mg/kg body weight every 2 weeks as an IV infusion for up to 52 weeks.

    Primary: Change From Baseline in six-Minute Walk Test (6MWT) for Participants Greater Than or Equal to (>=) 5-Year old at Month 12

    Close Top of page
    End point title
    Change From Baseline in six-Minute Walk Test (6MWT) for Participants Greater Than or Equal to (>=) 5-Year old at Month 12 [1]
    End point description
    The 6MWT is a practical simple test that requires a 100-ft hallway but no exercise equipment or advanced training for technicians. This test measures the distance that a participant can quickly walk on a flat, hard surface in a period of 6 minutes. It evaluates the global and integrated responses of all the systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism. Baseline was defined as the last available value before the treatment. The primary endpoint is estimated based on last observation carried forward (LOCF) method. Intent-to-treat (ITT) population included all enrolled participants treated with alglucosidase alfa.
    End point type
    Primary
    End point timeframe
    Baseline (Day 1) and Month 12
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: As the endpoint was descriptive in nature, no statistical analysis was provided.
    End point values
    Alglucosidase alfa
    Number of subjects analysed
    41
    Units: Meters
        arithmetic mean (confidence interval 95%)
    43.637 (17.461 to 69.813)
    No statistical analyses for this end point

    Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) for all Participants

    Close Top of page
    End point title
    Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) for all Participants [2]
    End point description
    An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as the AEs that developed, worsened or became serious during the treatment-emergent period (defined as the time from first dose of study treatment [Day 1] up to 30 days after the last dose of study treatment). A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was a medically important event. Safety population included all the participants who actually received at least 1 dose or part of a dose of study treatment.
    End point type
    Primary
    End point timeframe
    From first dose of study drug (Day 1) up to 30 days after last dose, approximately 14.4 months
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: As the endpoint was descriptive in nature, no statistical analysis was provided.
    End point values
    Alglucosidase alfa
    Number of subjects analysed
    41
    Units: Participants
        Any TEAE
    32
        Any TESAE
    7
    No statistical analyses for this end point

    Primary: Change From Baseline in Percent Predicted Forced Vital Capacity (%FVC) in Upright Position for Participants >=5-Year old at Month 12

    Close Top of page
    End point title
    Change From Baseline in Percent Predicted Forced Vital Capacity (%FVC) in Upright Position for Participants >=5-Year old at Month 12 [3]
    End point description
    FVC is a measurement of pulmonary function which is defined as the volume of air that can forcibly be blown out after full inspiration. It was assessed using the spirometry system with the participant in upright seated position. Percent of predicted FVC = (actual FVC measurement)/(predicted value of FVC) x 100. Baseline was defined as the last available value before the treatment. The endpoint is estimated based on LOCF method. ITT population included all enrolled participants treated with alglucosidase alfa.
    End point type
    Primary
    End point timeframe
    Baseline (Day 1) and Month 12
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: As the endpoint was descriptive in nature, no statistical analysis was provided.
    End point values
    Alglucosidase alfa
    Number of subjects analysed
    41
    Units: Percentage of Predicted FVC
        arithmetic mean (confidence interval 95%)
    2.430 (-0.852 to 5.713)
    No statistical analyses for this end point

    Secondary: Change From Baseline in Maximal Inspiratory Pressure (MIP) in Upright Position for Participants >=5-Year old at Week 52

    Close Top of page
    End point title
    Change From Baseline in Maximal Inspiratory Pressure (MIP) in Upright Position for Participants >=5-Year old at Week 52
    End point description
    MIP is a measurement of inspiratory muscle strength which is defined as how much air pressure force a participant creates by inhaling through the mouth as hard as possible. It was assessed using the pneumography with the participant in upright seated position. Baseline was defined as the last available value before the treatment. ITT population included all enrolled participants treated with alglucosidase alfa. Only those participants with data collected at Baseline and at Week 52 are reported.
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1) and Week 52
    End point values
    Alglucosidase alfa
    Number of subjects analysed
    31
    Units: centimeter of water column (cmH2O)
        least squares mean (confidence interval 95%)
    2.059 (-0.582 to 4.699)
    No statistical analyses for this end point

    Secondary: Change From Baseline in Maximal Expiratory Pressure (MEP) in Upright Position for Participants >=5-Year old at Week 52

    Close Top of page
    End point title
    Change From Baseline in Maximal Expiratory Pressure (MEP) in Upright Position for Participants >=5-Year old at Week 52
    End point description
    MEP is a measurement of expiratory muscle strength which is defined as the greater pressure generated during maximal expiration. It was assessed using the pneumography with the participant in upright seated position. Baseline was defined as the last available value before the treatment. ITT population included all enrolled participants treated with alglucosidase alfa. Only those participants with data collected at Baseline and at Week 52 are reported.
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1) and Week 52
    End point values
    Alglucosidase alfa
    Number of subjects analysed
    31
    Units: cmH2O
        least squares mean (confidence interval 95%)
    0.073 (-2.921 to 3.066)
    No statistical analyses for this end point

    Secondary: Change From Baseline in Manual Muscle Test (MMT) for Participants >=5-Year old at Week 52

    Close Top of page
    End point title
    Change From Baseline in Manual Muscle Test (MMT) for Participants >=5-Year old at Week 52
    End point description
    MMT was assessed according to expanded Medical Research Council (MRC) scale. MMT is used to measure body strength for deltoid muscle, quadriceps femoris, iliopsoas, and neck stretch flexor. Each individual item score range: 0 to 5 points with subdivisions in + or -, where a plus sign corresponds to an increase of one-third of score point and minus sign corresponds to a decrease of one-third of score point. Total scores are a sum of each individual item score, ranging from 0 (no muscle strength) to 40 (high muscle strength) with higher scores indicating better muscle strength. Baseline was defined as the last available value before the treatment. ITT population included all enrolled participants treated with alglucosidase alfa. Only those participants with data collected at Baseline and at Week 52 are reported.
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1) and Week 52
    End point values
    Alglucosidase alfa
    Number of subjects analysed
    36
    Units: Score on a scale
        least squares mean (confidence interval 95%)
    2.53 (1.559 to 3.493)
    No statistical analyses for this end point

    Secondary: Change From Baseline in Quick Motor Function Test (QMFT) Scores for Participants >=5-Year old at Week 52

    Close Top of page
    End point title
    Change From Baseline in Quick Motor Function Test (QMFT) Scores for Participants >=5-Year old at Week 52
    End point description
    The QMFT is a reliable and valid test for assessing motor function in participants with Pompe’s disease. QMFT comprised of 16 items specifically difficult for participants with Pompe’s disease. Each item was scored separately on a 5-point ordinal scale which ranged from 0 to 4; higher scores indicated better outcomes. Total QMFT score was obtained by adding the scores of all items and ranged from 0 (unable to perform motor function tests) to 64 (normal muscle function); higher scores represented better outcomes. Baseline was defined as the last available value before the treatment. ITT population included all enrolled participants treated with alglucosidase alfa. Only those participants with data collected at Baseline and at Week 52 are reported.
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1) and Week 52
    End point values
    Alglucosidase alfa
    Number of subjects analysed
    37
    Units: Score on a scale
        least squares mean (confidence interval 95%)
    5.6 (4.41 to 6.81)
    No statistical analyses for this end point

    Secondary: Change From Baseline in 12-Item Short-Form Health Survey Scores for Participants >=5-Year old at Week 52

    Close Top of page
    End point title
    Change From Baseline in 12-Item Short-Form Health Survey Scores for Participants >=5-Year old at Week 52
    End point description
    The 12-Item Short Form Health Survey (SF-12) which was developed for the medical outcomes evaluation of participants with chronic conditions. The SF-12 has 12 questions covering 8 health domains commonly represented in health surveys: physical functioning, role functioning physical, bodily pain, general health, vitality, social functioning, role functioning emotional, and mental health. Results are expressed in terms of 2 meta-scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The score ranges from 0 to 100; higher scores indicated better outcomes. Baseline was defined as the last available value before the treatment. ITT population included all enrolled participants treated with alglucosidase alfa. Only those participants with data collected at Baseline and at Week 52 are reported.
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1) and Week 52
    End point values
    Alglucosidase alfa
    Number of subjects analysed
    37
    Units: Score on a scale
    least squares mean (confidence interval 95%)
        PCS-12
    3.762 (1.252 to 6.271)
        MCS-12
    0.608 (-1.986 to 3.203)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Adverse events: From first dose of study treatment (Day 1) up to 30 days after last dose, approximately 14.4 months. All-cause mortality (death): From first dose of study treatment (Day 1) up to end of study, approximately 40.56 months.
    Adverse event reporting additional description
    Analysis was performed on Safety population.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    27.0
    Reporting groups
    Reporting group title
    Alglucosidase alfa
    Reporting group description
    Participants received alglucosidase alfa at a dose of 20 mg/kg body weight every 2 weeks as an IV infusion for up to 52 weeks.

    Serious adverse events
    Alglucosidase alfa
    Total subjects affected by serious adverse events
         subjects affected / exposed
    7 / 41 (17.07%)
         number of deaths (all causes)
    0
         number of deaths resulting from adverse events
    0
    Injury, poisoning and procedural complications
    Fracture
         subjects affected / exposed
    1 / 41 (2.44%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Lumbar Vertebral Fracture
         subjects affected / exposed
    1 / 41 (2.44%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nervous system disorders
    Cerebral Infarction
         subjects affected / exposed
    1 / 41 (2.44%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Intestinal Obstruction
         subjects affected / exposed
    1 / 41 (2.44%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Respiratory Failure
         subjects affected / exposed
    1 / 41 (2.44%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Pneumonia
         subjects affected / exposed
    2 / 41 (4.88%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Pneumonia Bacterial
         subjects affected / exposed
    1 / 41 (2.44%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Alglucosidase alfa
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    24 / 41 (58.54%)
    Investigations
    Blood Creatine Phosphokinase Increased
         subjects affected / exposed
    9 / 41 (21.95%)
         occurrences all number
    10
    Blood Lactate Dehydrogenase Increased
         subjects affected / exposed
    7 / 41 (17.07%)
         occurrences all number
    7
    Carbon Dioxide Combining Power Increased
         subjects affected / exposed
    3 / 41 (7.32%)
         occurrences all number
    5
    Creatinine Urine Decreased
         subjects affected / exposed
    3 / 41 (7.32%)
         occurrences all number
    4
    Electrocardiogram T Wave Peaked
         subjects affected / exposed
    2 / 41 (4.88%)
         occurrences all number
    2
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    3 / 41 (7.32%)
         occurrences all number
    3
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    3 / 41 (7.32%)
         occurrences all number
    4
    Nasal Turbinate Hypertrophy
         subjects affected / exposed
    1 / 41 (2.44%)
         occurrences all number
    1
    Oropharyngeal Pain
         subjects affected / exposed
    3 / 41 (7.32%)
         occurrences all number
    3
    Pulmonary Hypertension
         subjects affected / exposed
    4 / 41 (9.76%)
         occurrences all number
    4
    Respiratory Failure
         subjects affected / exposed
    1 / 41 (2.44%)
         occurrences all number
    1
    Skin and subcutaneous tissue disorders
    Dermatitis
         subjects affected / exposed
    1 / 41 (2.44%)
         occurrences all number
    2
    Infections and infestations
    Covid-19
         subjects affected / exposed
    4 / 41 (9.76%)
         occurrences all number
    4
    Nasopharyngitis
         subjects affected / exposed
    2 / 41 (4.88%)
         occurrences all number
    2
    Upper Respiratory Tract Infection
         subjects affected / exposed
    10 / 41 (24.39%)
         occurrences all number
    13

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    29 May 2020
    Statistical considerations were modified. Updates were made in study flow chart, determination of sample size, compliance, and graphical study design. Analysis of primary and secondary efficacy endpoints were modified. Multiplicity considerations and other analyses were updated. Clarifications were provided in duration of study participation for each participant, selection of participants and visit schedule. Safety and other safety endpoints were updated.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 21:03:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA